Skip to content

Analgesic Efficacy of Continuous SESP vs Continuous FICB After Hip Arthroplasty

Continuous Sacral Erector Spinae Plane Block Versus Continuous Fascia Iliaca Compartment Block for Postoperative Analgesia After Total Hip Arthroplasty: a Randomized Clinical Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07516795
Acronym
SESP-HIP
Enrollment
60
Registered
2026-04-08
Start date
2026-04-09
Completion date
2026-06-30
Last updated
2026-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthroplasty, Replacement, Hip, Pain, Postoperative; Anesthesia, Regional

Keywords

Sacral Erector Spinae Plane Block, Fascia Iliaca Compartment Block, Regional Anesthesia, Continuous Analgesia

Brief summary

The primary objective of this prospective, randomized, observer-blinded controlled trial is to compare the postoperative analgesic efficacy of continuous intermediate-approach sacral erector spinae plane (SESP) block versus continuous supra-inguinal fascia iliaca compartment block (FICB) in adult patients undergoing elective posterior-approach total hip arthroplasty under spinal anesthesia. Sixty patients will be randomly allocated to receive either a continuous SESP block or a continuous supra-inguinal FICB. Both techniques involve an initial bolus of 30 mL 0.1% ropivacaine followed by intermittent boluses of 20 mL 0.1% ropivacaine every 6 hours for 72 hours via an indwelling catheter, in addition to standardized multimodal analgesia. The primary outcome is cumulative morphine milligram equivalents (MME) consumption over the first 72 postoperative hours. Secondary outcomes include pain scores at rest and during movement (NRS), quality of recovery (QoR-15) at 72 hours, motor function (modified Bromage scale), and adverse events. We hypothesize that continuous SESP block will provide superior opioid-sparing analgesia compared with continuous supra-inguinal FICB while maintaining comparable pain control, quality of recovery, and motor function preservation.

Detailed description

Effective postoperative pain management after total hip arthroplasty (THA) via the posterior approach remains challenging because the surgical site receives innervation from both the lumbar and sacral plexuses. Multimodal analgesia incorporating regional anesthesia techniques is recommended to minimize opioid consumption and facilitate early rehabilitation. However, the optimal continuous regional technique for posterior THA has not been clearly established. This prospective, randomized, observer-blinded trial compares two continuous ultrasound-guided regional analgesia techniques in patients undergoing elective posterior-approach THA under spinal anesthesia. Eligible adult patients (ASA I-III) are randomized in a 1:1 ratio to receive either continuous intermediate-approach sacral erector spinae plane (SESP) block or continuous supra-inguinal fascia iliaca compartment block (FICB). In the SESP group, with the patient in the lateral decubitus position, a catheter is placed in the interfascial plane between the erector spinae muscle and the intermediate sacral crest under ultrasound guidance. In the FICB group, with the patient supine, a catheter is placed in the fascia iliaca compartment using the supra-inguinal approach with identification of the characteristic bow-tie sign. Both groups receive an initial bolus of 30 mL 0.1% ropivacaine followed by intermittent boluses of 20 mL 0.1% ropivacaine every 6 hours for a total of 72 hours via the indwelling catheter. All patients receive standardized multimodal analgesia consisting of intravenous paracetamol 1 g every 8 h and diclofenac 75 mg every 12 h, with intravenous fentanyl PCA as rescue analgesia. The primary outcome is cumulative opioid consumption expressed as morphine milligram equivalents (MME) during the first 72 postoperative hours. Key secondary outcomes include NRS pain scores at rest and during hip flexion at multiple time points up to 72 hours, the Quality of Recovery-15 (QoR-15) score at 72 hours, motor function assessed by the modified Bromage scale at 24, and the incidence of adverse events. Catheter boluses were administered every 6 h by the anaesthesiologists who performed the blocks, who were necessarily unblinded and collected no outcome data. Outcome assessors, the ward nurses administering multimodal analgesia and managing the PCA devices, and data analysts remained blinded to group allocation. Patients could not be blinded due to the distinct anatomical locations of the two interventions. This trial aims to determine whether continuous SESP block provides clinically meaningful opioid-sparing benefits compared with continuous supra-inguinal FICB in patients undergoing posterior THA, without compromising recovery quality or safety.

Interventions

PROCEDUREContinuous Sacral Erector Spinae Plane Block

Under ultrasound guidance, a catheter is inserted into the sacral erector spinae plane. An initial bolus of 30 mL of 0.1% ropivacaine is injected at catheter placement, followed by intermittent boluses of 20 mL of 0.1% ropivacaine every 6 hours for 72 hours via the indwelling catheter.

Under ultrasound guidance, a catheter is inserted deep to the fascia iliaca. An initial bolus of 30 mL of 0.1% ropivacaine is injected at catheter placement, followed by intermittent boluses of 20 mL of 0.1% ropivacaine every 6 hours for 72 hours via the indwelling catheter.

Sponsors

Bach Mai Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Outcome assessors, ward nurses administering multimodal analgesia, and data analysts were blinded to group allocation. Patients and anesthesiologists performing the blocks could not be blinded due to the distinct anatomical locations of the two interventions.

Intervention model description

Eligible patients are randomly assigned to one of two parallel groups (SESP or FICB) in a 1:1 ratio.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Adult patients aged 18 to 80 years. Scheduled for elective primary unilateral total hip arthroplasty due to osteoarthritis (not due to hip fracture or trauma). American Society of Anesthesiologists (ASA) physical status I, II, or III. Ability to understand and cooperate with study procedures, including postoperative pain assessment using the Numeric Rating Scale (NRS) and follow-up evaluations. Provided written informed consent to participate in the study.

Exclusion criteria

Patient refusal to participate or inability to provide informed consent. Contraindications to regional anesthesia or peripheral nerve blocks (e.g., coagulopathy, therapeutic anticoagulation, infection at the injection site, or severe spinal deformity). Known allergy or hypersensitivity to local anesthetics (ropivacaine or bupivacaine). Previous surgery on the same hip. Severe cardiopulmonary disease (e.g., NYHA class III-IV, severe COPD) that may interfere with postoperative recovery assessment. Neurological disorders affecting the lower extremities (e.g., stroke with residual motor deficit, peripheral neuropathy). Cognitive impairment or inability to cooperate with catheter care and follow-up assessments. Pregnancy or breastfeeding.

Design outcomes

Primary

MeasureTime frameDescription
Cumulative Morphine Milligram Equivalents (MME) Consumption at 72 Hours Postoperatively0 to 72 hours after block placementTotal cumulative consumption of rescue opioid analgesics administered from the completion of surgery until 72 hours postoperatively, converted to intravenous morphine milligram equivalents (MME). A higher value indicates greater opioid requirement.

Secondary

MeasureTime frameDescription
Cumulative MME Consumption at 24 Hours and 48 Hours Postoperatively0-24 h and 24-48 h after block placementTotal rescue opioid consumption (MME) during 0-24 h and 24-48 h intervals.
Pain scores at rest (NRS)0 to 72 hours after block placementPain scores at rest assessed using 0-10 NRS at 0, 2, 6, 12, 24, 36, 48, and 72 hours after block placement.
Pain Intensity During Movement (NRS)0 to 72 hours after block placementPain scores during hip flexion (active movement) assessed using 0-10 NRS at the same time points.
Quality of Recovery-15 (QoR-15) Score at 72 Hours72 hours after block placementTotal QoR-15 score (range 0-150) assessing quality of recovery at 72 hours postoperatively. Higher scores indicate better recovery.
Motor Function (Modified Bromage Scale)24 hours after block placementMotor block assessed by modified Bromage scale (0 = no motor block, 3 = complete motor block) at 24 hours after block placement.
Incidence of Adverse Events0 to 72 hours after block placementNumber of participants with nausea/vomiting, pruritus, urinary retention, catheter-related complications (dislodgement/occlusion), local anesthetic systemic toxicity, hematoma, infection, or neurological deficit.

Countries

Vietnam

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 2, 2026